Antag Therapeutics is focused on developing innovative therapeutic peptides aimed at modulating GIP (Gastric Inhibitory Polypeptide) biology, which plays a significant role in the regulation of metabolism and cardiovascular health. The company’s research is rooted in extensive studies conducted at the University of Copenhagen, particularly the work of Professors Jens Juul Holst and Mette Rosenkilde, who discovered a novel endogenous peptide antagonist. This antagonist has been characterized through various human intervention studies, leading to the creation of first-in-class therapeutic peptides that serve as optimized analogues of a natural GIP receptor inhibitor. These peptides are designed to address critical health issues such as obesity and postural orthostatic tachycardia syndrome (POTS), conditions that currently lack effective pharmacological treatments.

The therapeutic focus of Antag Therapeutics is particularly relevant given the global obesity epidemic, which affects over 650 million individuals and is associated with numerous comorbidities, including type 2 diabetes and cardiovascular diseases. Additionally, POTS, which impacts around 3 million people in the U.S., predominantly women, is characterized by debilitating symptoms and a significant reduction in quality of life. Antag Therapeutics aims to fill the treatment gap for these conditions by advancing their lead molecule, AT-7687, through clinical development, with the recent FDA clearance of their Investigational New Drug (IND) application marking a pivotal step in their mission to provide new therapeutic options for patients suffering from obesity and cardiometabolic diseases.

Denmark

Antag Therapeutics is a preclinical stage biotechnology company committed to the development of novel therapeutic peptides for metabolic – and cardiovascular autonomic diseases.

Antag Therapeutics is based on decades of research from the University of Copenhagen focusing on understanding and targeting incretin physiology. Our therapeutic peptides are based on a novel endogenous peptide antagonist discovered by the research teams of Professors Jens Juul Holst and Mette Rosenkilde that has been characterized in several human intervention studies.

Antag Therapeutics

Company Details